Acadia’s Share Price Tumbles As Pimavanserin NDA Is Delayed A Second Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says delay is due to manufacturing scale-up work and does not reflect any change in Parkinson’s psychosis drug’s efficacy or safety profile. In tandem with the news, CEO Hacksell retired, replaced on interim basis by CFO Davis.